PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12712987

[The pharmaceutical industry during the Second World War: issues and evolution].

Bruno Bonnemain
View original source ↗Export metadata ↓

Abstract

During the Second World War, French pharmaceutical industry was facing several crises at the same time: economic, social and political crisis, in its relationship with the German occupying forces and the Vichy regime. However, the industrial pharmacy continued its investments and innovation: several specialties were born. Other specialties are largely increasing their sales as they replace missing food (sugar, oil). Relationship with the occupying forces are first to try to escape constraints that are imposed to the companies. But contracts signed with German companies are obviously related to the defeated position of France. Allied are also a source of breach between French companies and their subsidiaries abroad (UK or USA). In this context, the new French law of September 11, 1941 on French Pharmacy appears for Vichy's regime and German occupying forces as a way among others to control the French pharmaceutical industry.

Explore related subjects

Drug IndustryEconomics, PharmaceuticalFranceGermanyHistory, 20th CenturyPoliticsWarfareEnglish AbstractHistorical ArticleJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bruno Bonnemain. 2002. [The pharmaceutical industry during the Second World War: issues and evolution].. https://pubmed.ncbi.nlm.nih.gov/12712987/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics.

The ability to manage risk depends critically on an understanding of the degree to which a known risk is balanced by the probability of a clinical benefit. Despite the massive emphasis on risk and risk management in the past few years and the long-term focus on defining benefit in the regulatory system, considerable uncertainty remains about the methods of defining benefit and how to operationalize this knowledge. In this 'think tank,' part of a larger series on risk management, issues were divided into those that can be identified before a study is initiated, those that commonly arise after a study is completed, biomarkers and surrogates, use of benefit findings in defining quality and performance indicators, implementation of findings into health systems and formularies, and methods of comparative trials. Key categories for the establishment of a research agenda to fill in gaps in our understanding of assessing benefit were developed by the group.

Drug Industry↗
PubMed2007

Discussion point: should governments buy drug patents?

Between just 1995 and 2003, the number of new chemical entities fell from 45 to 25, while the costs increased by two and a half times in the same period. Firms in the USA accounted for more than half of biotech drugs from 1982 to 2003. European firms are losing competitiveness. In this hostile environment for investment in pharmaceutical R&D, providing quick access to market for real innovations is the main challenge for regulatory agencies. More initiatives, more entrepreneurial spirit and easier work regulation are needed to facilitate the growth of firms in this field, especially in emerging economies like the Spanish. A new open source model proposes the use of pre-competitive public platforms formed by young and qualified human capital carrying out research in areas not sufficiently attractive for private initiatives, followed by the introduction of pharmaceutical companies to carry out the clinical research. The last step would be fast and effective approval by assessment agencies. Governments should, therefore, facilitate the regulation of socially effective innovations, bringing in manufacturers to take part in the post-clinical trial period after entering the market. The gathering of incentives between regulatory agencies and pharmaceutical industry must be approached through innovation and authorization stimulating systems.

Drug Industry↗